Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate

W Pollock, K Clarke, K Gallagher, J Hall, E Luckhurst, R McEvoy, J Melny, J Neil, A Nikoloutsopoulos, T Thompson, M Trevisin, J Savige

Background: The "International consensus statement on testing and reporting antineutrophil cytoplasmic antibodies (ANCA)" advocates screening by indirect immunofluorescence (IIF), but external quality assessment programmes often demonstrate different IIF patterns for a single serum.

Aim: To determine whether the variation in IIF patterns can be attributed solely to errors in interpretation.

Methods: This study compared the IIF patterns produced by four sera (two with cytoplasmic or C-ANCA; one with perinuclear or P-ANCA with myeloperoxidase (MPO) specificity; and one P-ANCA without MPO specificity) that were tested in 11 different laboratories. The sera were examined according to individual laboratory protocols at dilutions of 1/10 to 1/40 using P1 (n = 4), P2 (n = 2), P3 (n = 2), or in house (n=5) neutrophil preparations and conjugates from manufacturers C1 (n = 3), C2 (n = 1), C3 (n = 2), C4 (n = 1), C5 (n = 2), and C6 (n = 2). The IIF patterns were noted in each laboratory, the testing repeated, and the fluorescent patterns photographed and subsequently discussed at a meeting of the Australian ANCA study group.

Results: All IIF patterns described in individual laboratories were confirmed on retesting and by the ANCA study group. Neutrophil substrates produced commercially or in house varied in their ability to demonstrate cytoplasmic granularity and interlobular accentuation, which distinguish between "C-ANCA" and "C-ANCA (atypical)", All commercial and in house neutrophil substrates demonstrated neutrophil nuclear extension of P-ANCA fluorescence, which correlates with MPO specificity. However, eight assays (eight of 43) from eight laboratories resulted in IIF patterns different from those usually seen. One of these produced a C-ANCA (atypical) rather than a C-ANCA pattern. The other seven resulted in at least some cytoplasmic fluorescence when the consensus pattern was P-ANCA with (n = 4) or without (n = 3) MPO specificity. These assays used three different commercial and one in house neutrophil substrate, and six different conjugates, with anti-IgG, anti-(Fab)2, anti-IgG (heavy and light chain), and anti-G, A, and M activity. Four of the seven assays tested on commercial substrates had used the manufacturer’s conjugates.

Conclusions: This study indicates that the variation in IIF patterns seen with ANCA positive sera tested in different laboratories does not necessarily result from errors in the interpretation of patterns and cannot be attributed solely to the use of a particular neutrophil substrate or conjugate, or to the use of substrate from one manufacturer and conjugate from another.

Antineutrophil cytoplasmic antibodies (ANCA) are autoantibodies directed at antigens found in the cytoplasmic granules of neutrophils and monocytes. These antibodies occur at presentation in most patients with active Wegener's granulomatosis or microscopic polyangiitis (reviewed in Savige and colleagues). The "International consensus statement on testing and reporting antineutrophil cytoplasmic antibodies (ANCA)" advocates that all laboratories screen for ANCA by indirect immunofluorescence (IIF), and that any sera with cytoplasmic or perinuclear fluorescence, or nuclear fluorescence that might mask an ANCA, should be tested for both the major ANCA specificities, proteinase 3 (PR3) and myeloperoxidase (MPO) by enzyme linked immunosassay (ELISA). The conditions for IIF and the ELISAs have been described in detail.

"Cytoplasmic antineutrophil cytoplasmic antibodies (C-ANCA) have to be distinguished from C-ANCA (atypical), where the fluorescence is flatter, and there is no accentuation of the interlobular fluorescence or granular staining"

The consensus statement describes two fluorescence patterns that occur in patients with Wegener's granulomatosis and microscopic polyangiitis. Cytoplasmic fluorescence (C-ANCA) is diffuse cytoplasmic staining with coarse granular and central interlobular accentuation. It is seen in most patients with active generalised Wegener's granulomatosis, and is usually the result of PR3 specificity. With perinuclear fluorescence (P-ANCA), the nuclear lobes are outlined, and there is some nuclear extension when the specificity is MPO. MPO-ANCA occur in about 60% of patients with microscopic polyangiitis, but sometimes patients with microscopic polyangiitis have P-ANCA with PR3 specificity, or C-ANCA with PR3 or MPO specificity.

Abbreviations: ANCA, antineutrophil cytoplasmic antibodies; C-ANCA, cytoplasmic antineutrophil cytoplasmic antibodies; ELISA, enzyme linked immunosassay; IIF, indirect immunofluorescence; MPO, myeloperoxidase; P-ANCA, perinuclear antineutrophil cytoplasmic antibodies; PR3, proteinase 3
Immunofluorescent patterns produced by ANCA

Immunofluorescence patterns seen with four sera tested in 11 different laboratories

Table 1

<table>
<thead>
<tr>
<th>Serum A</th>
<th>Serum B</th>
<th>Serum C</th>
<th>Serum D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laboratory</td>
<td>PMN</td>
<td>GRI</td>
<td>P1</td>
</tr>
<tr>
<td>PMN</td>
<td>1/40</td>
<td>C4 IgG (H&amp;L), prediluted</td>
<td>400</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>P1</td>
<td>1/100</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>STG</td>
<td>1/40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>OC</td>
<td>1/20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| | | | | Neutrophil preparations and substrates from the same manufacturer have the same suffix; fluorescence is described as 0 to 3+; i0–3+, interlobular or central accentuation of cytoplasmic fluorescence; g0–3+, granularity of cytoplasmic fluorescence.

The observed IIF patterns were inconsistent with the consensus patterns in eight assays, each from a different laboratory (eight of 43) (table 1; fig 1). One of these produced a C-ANCA (atypical) rather than a C-ANCA pattern. The other seven resulted in at least some cytoplasmic fluorescence when the consensus pattern was P-ANCA with (n = 4) or without (n = 3) MPO specificity. The intensity of fluorescence for all sera varied by 1+ at most between assays and laboratories.

METHODS

Sera with C-ANCA and PR3 specificity (n = 2) (producing 3+ or 2+ fluorescence), P-ANCA with MPO specificity (3+) (n = 1), and P-ANCA without MPO specificity (3+) (n = 1) were selected by the reference laboratory that coordinates external quality assessment testing for ANCA in Australia. Sera were chosen that were typical of the C-ANCA found in Wegener’s granulomatosis and the P-ANCA found in microscopic polyangiitis or inflammatory bowel disease. None of the sera contained antinuclear antibodies when tested on HEp2 cells.

Each serum was distributed to 11 laboratories and tested with the neutrophil substrates, serum dilutions, and conjugate type and dilutions used routinely in that laboratory (table 1). Substrates and conjugates have been coded, and P1 and C1, P2 and C2, etc are from the same manufacturer. All in house neutrophil preparations were made according to the published method. Slides were then examined using ultraviolet microscopy, and the IIF patterns described and strength of fluorescence graded from 0 (negative) to 3+ (strong). The process was repeated, the fluorescence patterns were photographed, and the patterns and intensity of staining were subsequently characterised by members of the Australian ANCA study group at a face to face meeting. The “consensus” pattern was the pattern seen in most laboratories.

RESULTS

All test sera were positive for ANCA by IIF in each of the 11 laboratories. All fluorescence patterns were consistent between the first and second testing in each laboratory, and with the description at the meeting of the Australian ANCA study group. Thus, variations in IIF patterns cannot be attributed solely to errors in interpretation.

The observed IIF patterns were inconsistent with the consensus patterns in eight assays, each from a different laboratory (eight of 43) (table 1; fig 1). One of these produced a C-ANCA (atypical) rather than a C-ANCA pattern. The other seven resulted in at least some cytoplasmic fluorescence when the consensus pattern was P-ANCA with (n = 4) or without (n = 3) MPO specificity. The intensity of fluorescence for all sera varied by 1+ at most between assays and laboratories.

Neutrophil substrates varied in their ability to demonstrate the consensus IIF patterns. In general, C-ANCA was demonstrated well but substrates differed in their ability to distinguish between a C-ANCA and C-ANCA (atypical). P1 neutrophils demonstrated C-ANCA in all four laboratories and the cytoplasmic granularity and central accentuation were
more prominent and more consistent than with other neutrophil preparations. P2 neutrophils were satisfactory where there was strong cytoplasmic fluorescence, but the central accentuation and granularity of weaker cytoplasmic staining were not easily demonstrated, resulting in a C-ANCA being interpreted as a C-ANCA (atypical). Both the P3 and in house neutrophils were too small for cytoplasmic fluorescence to be demonstrated clearly.

All three commercial and three in house neutrophil substrates consistently demonstrated nuclear extension of perinuclear fluorescence with sera containing P-ANCA with MPO specificity. However seven assays of sera containing P-ANCA demonstrated (mostly) additional cytoplasmic fluorescence with each of the three different commercial substrates and one in house assay. In one case only cytoplasmic fluorescence was present.

Of the eight assays that resulted in IIF patterns that differed from the consensus, seven used commercial neutrophil substrates and one an in house substrate. Conjugates included anti-IgG, anti-F(\(\text{ab}'\))\(_2\), anti-IgG (heavy and light chains), and anti-IgG, A, and M. All six conjugates produced an abnormal IIF pattern on at least one occasion. Of the seven assays tested on commercial substrates, four had been performed using the manufacturer’s conjugates, and three had not.

**DISCUSSION**

The 11 laboratories participating in our study used different patient serum dilutions, neutrophil substrates, conjugates, and microscope magnifications to examine the test sera. All four sera were considered positive for ANCA by IIF in all the laboratories, most patterns were correctly identified as C-ANCA or P-ANCA, and the fluorescence intensities were generally consistent between assays and laboratories. All descriptions of IIF patterns were confirmed on retesting in individual laboratories and on review by the Australian ANCA study group. The participating laboratories comprised the ANCA study group, members of which have a particular interest and expertise in ANCA testing. This may have biased our findings away from those obtained in inexperienced laboratories, where variations in IIF patterns may result from observer error. However, our study demonstrates that variations in ANCA IIF patterns do not necessarily result from the misinterpretation of patterns, but may result from other, probably technical, factors.

In our study, neutrophil substrates from different manufacturers varied in their ability to demonstrate interlobular fluorescence and cytoplasmic granularity, and thus to differentiate between a C-ANCA and C-ANCA (atypical) pattern. However, most laboratories distinguished successfully between these patterns. Although all three commercial and three in house neutrophil substrates demonstrated the nuclear extension of P-ANCA that correlates with MPO specificity, there were, in general, more problems testing sera containing P-ANCA.

Eight assays from eight different laboratories resulted in IIF descriptions that differed from the consensus patterns. These were mostly caused by additional cytoplasmic fluorescence.
and were found in sera with P-ANCA with or without MPO specificity. However, this preliminary study suggests that the development of cytoplasmic fluorescence in sera containing P-ANCA cannot be attributed solely to the use of a particular neutrophil substrate or conjugate, or to the combination of substrate from one manufacturer and conjugate from another. The explanation for the development of cytoplasmic fluorescence is unclear but may relate to the use of alcohol in neutrophil fixation because this permeabilises the membranes and allows the normally cytoplasmic MPO to diffuse around the nucleus to produce the perinuclear pattern. Cytoplasmic fluorescence may also result from delays in examining the substrate, which allows the perinuclear MPO to diffuse back into the cytoplasm. Finally, cytoplasmic fluorescence may result from the use of polyclonal antiserum that detects additional IgA or IgM ANCA.

“The explanation for the development of cytoplasmic fluorescence is unclear but may relate to the use of alcohol in neutrophil fixation because this permeabilises the membranes”

The manufacturers of the P3 substrate have dealt with the issue of small neutrophil cytoplasmic volume.
Immunofluorescent patterns produced by antineutrophil cytoplasmic antibodies (ANCA) vary depending on neutrophil substrate and conjugate

W Pollock, K Clarke, K Gallagher, J Hall, E Luckhurst, R McEvoy, J Melny, J Neil, A Nikoloutsopoulos, T Thompson, M Trevisin and J Savige

doi: 10.1136/jcp.55.9.680

Updated information and services can be found at:
http://jcp.bmj.com/content/55/9/680

These include:

**References**

This article cites 8 articles, 2 of which you can access for free at:
http://jcp.bmj.com/content/55/9/680#BIBL

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

Immunology (including allergy) (1664)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/